Anthracycline-Based Chemotherapy
The prognostic and predictive power of redox rotein expression for anthracycline based chemotherapy response in locally advanced breast cancer
... neoadjuvant anthracycline-based ...before chemotherapy to allow pathological diagno- sis and evaluation of biological ...of anthracycline- based therapy (5-fluorouracil (5-FU) 500 mg/m ...
11
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
... to anthracycline-based chemotherapy looks greater than previously ...to chemotherapy were described in 2001 by McGrory in 2 of 6 metastatic EMC patients re- sponsive to a multi-agent ...
7
Tumor infiltrating lymphocytes predict response to anthracycline based chemotherapy in estrogen receptor negative breast cancer
... neoadjuvant anthracycline/taxane therapy in two large breast cancer cohorts, providing compelling evi- dence that TIL could potentially serve as predictive mar- kers for anthracycline-based ...
13
Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline based chemotherapy: study protocol for a randomized controlled trial
... receiving anthracycline- based chemotherapy, we performed a randomized con- trolled trial to evaluate the cardioprotective effects and safety of ...receiving anthracycline-based ...
7
<p>A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy</p>
... Categoric data were compared via Pearson ’ s chi-square or Fisher ’ s test, whereas continuous variables were compared via Mann – Whitney and Kruskal – Wallis tests. Optimal cut- off values of nPD-L1 level and FoxP3+Treg ...
10
PubMedCentral-PMC5226883.pdf
... adjuvant chemotherapy regimens that include anthracyclines where breast cancer recurrence and mortality benefits are expected to be substantial, but should provide pause when chemotherapy benefits are ...
18
Advanced Pleomorphic Liposarcomas: Clinical Outcome and Impact of Chemotherapy
... of anthracycline-based chemotherapy in STS included miscellaneous histological subtypes and showed objective response rates ranging between 9 and 27% for doxorubicin as single agent and between 35 ...
6
Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
... Anthracycline-based chemotherapy remains the mainstay of therapy in soft tissue sarcomas (STS) since its introduction into the treatment algorithm in the 70’s ...
11
High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer
... received anthracycline-based chemotherapy (anthracycline plus cyclophosphamide or anthracycline plus cyclophosphamide and 5-fluorouracil) and 43 patients had received ...
10
WEIGHT CHANGES DURING CHEMOTHERAPY AND PROGNOSTIC OUTCOME IN BREAST CANCER: A PRELIMINARYASSESSMENT IN SINGLE CENTRE COHORT
... study based on a hospital retrospective cohort has been conducted at Hospital Sultanah Nur Zahirah (HSNZ), Kuala Terengganu, ...completed chemotherapy treatment between January 2005 and December ...received ...
8
Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
... during chemotherapy in the ...of chemotherapy and benefit- ted radiologically [CR/PR or SD]) to have a better overall HRQoL score at baseline than the chemotherapy group at baseline suggesting a ...
24
First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma
... for chemotherapy. As age is an independent risk factor for anthracycline induced cardiomyopathy [30] we have adopted an approach of optimising cardiovascular health with cardio-oncology input prior to ...
6
<p>Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date</p>
... First, this study enrolled patients who were naïve to sys- temic therapy for advanced disease. Only 13 of 123 evaluable patients received neoadjuvant or adjuvant chemotherapy. Presumably, most of this subgroup ...
16
Diagnosis of Chemotherapy-Induced Cardiotoxicity
... to chemotherapy is classified in two groups. Type I chemotherapy-related myocardial dysfunction is usually secondary to oxidative stress (typically anthracycline-induced) and results in cardiomyocyte ...
8
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
... (MFHs). However, a significant subset of tumors initially diagnosed as MFH showed a specific line of differenti- ation (lipogenic, neurogenic, myogenic, or non- sarcomatous) [9–12]. “MFH” is now considered an obso- lete ...
11
Evaluation of novel biomarkers in the detection of chemotherapy mediated cardiac and kidney injury
... Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.. Seidman A, H[r] ...
268
Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes
... and chemotherapy, which seek to eradicate most tumor cells and reduce the tumor burden to a minimal level, thus facilitating therapies target- ing residual or metastatic ...
9
Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study
... cancer chemotherapy [1] with doxorubicin and epirubicin most frequently used ...ing chemotherapy was 3% by 3 years compared to 1% in an age matched cohort not receiving chemotherapy ...after ...
15
Prognostic and predictive value of TP53mutations in node positive breast cancer patients treated with anthracycline or anthracycline/taxane based adjuvant therapy: results from the BIG 02 98 phase III trial
... In this study, p53 mutations had no significant predic- tive value. This study adds to the conflicting body of clinical evidence regarding the potential clinical role of p53 as a single biomarker for prediction of ...
13
Prognostic and predictive value of Phospho p44/42 and pAKT in HER2 positive locally advanced breast cancer patients treated with anthracycline based neoadjuvant chemotherapy
... proliferation. In HER2-overexpressing MBC group, Gori (et al. found that Phospho-p44/42 and pAKT were not associated with the clinical outcome, although low Phospho-p44/42 expression showed a trend for associ- ation with ...
9